174 related articles for article (PubMed ID: 32069401)
1. Design, Synthesis, and Biological Evaluation of Imidazo[1,2-
Yu Y; Han Y; Zhang F; Gao Z; Zhu T; Dong S; Ma M
J Med Chem; 2020 Mar; 63(6):3028-3046. PubMed ID: 32069401
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluation of novel 3H-imidazole [4,5-b] pyridine derivatives as selective mTOR inhibitors.
Zhang L; Bu T; Bao X; Liang T; Ge Y; Xu Y; Zhu Q
Bioorg Med Chem Lett; 2017 Aug; 27(15):3395-3398. PubMed ID: 28633896
[TBL] [Abstract][Full Text] [Related]
3. (
Rageot D; Bohnacker T; Keles E; McPhail JA; Hoffmann RM; Melone A; Borsari C; Sriramaratnam R; Sele AM; Beaufils F; Hebeisen P; Fabbro D; Hillmann P; Burke JE; Wymann MP
J Med Chem; 2019 Jul; 62(13):6241-6261. PubMed ID: 31244112
[TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis and SAR in 2,4,7-Trisubstituted Pyrido[3,2-
Buron F; Rodrigues N; Saurat T; Hiebel MA; Bourg S; Bonnet P; Nehmé R; Morin P; Percina N; Corret J; Vallée B; le Guevel R; Jourdan ML; Bénédetti H; Routier S
Molecules; 2021 Sep; 26(17):. PubMed ID: 34500781
[TBL] [Abstract][Full Text] [Related]
5. Discovery and optimization of potent and selective imidazopyridine and imidazopyridazine mTOR inhibitors.
Peterson EA; Boezio AA; Andrews PS; Boezio CM; Bush TL; Cheng AC; Choquette D; Coats JR; Colletti AE; Copeland KW; DuPont M; Graceffa R; Grubinska B; Kim JL; Lewis RT; Liu J; Mullady EL; Potashman MH; Romero K; Shaffer PL; Stanton MK; Stellwagen JC; Teffera Y; Yi S; Cai T; La DS
Bioorg Med Chem Lett; 2012 Aug; 22(15):4967-74. PubMed ID: 22765895
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and evaluation of some 1,6-disubstituted-1H-benzo[d]imidazoles derivatives targeted PI3K as anticancer agents.
Ding HW; Yu L; Bai MX; Qin XC; Song MT; Zhao QC
Bioorg Chem; 2019 Dec; 93():103283. PubMed ID: 31585260
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel quinoline-based mTOR inhibitors via introducing intra-molecular hydrogen bonding scaffold (iMHBS): The design, synthesis and biological evaluation.
Ma X; Lv X; Qiu N; Yang B; He Q; Hu Y
Bioorg Med Chem; 2015 Dec; 23(24):7585-96. PubMed ID: 26596710
[TBL] [Abstract][Full Text] [Related]
8. Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR.
Martínez González S; Hernández AI; Varela C; Lorenzo M; Ramos-Lima F; Cendón E; Cebrián D; Aguirre E; Gomez-Casero E; Albarrán MI; Alfonso P; García-Serelde B; Mateos G; Oyarzabal J; Rabal O; Mulero F; Gonzalez-Granda T; Link W; Fominaya J; Barbacid M; Bischoff JR; Pizcueta P; Blanco-Aparicio C; Pastor J
Bioorg Med Chem Lett; 2012 Aug; 22(16):5208-14. PubMed ID: 22819764
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and bioevaluation of novel substituted triazines as potential dual PI3K/mTOR inhibitors.
Wu TT; Guo QQ; Chen ZL; Wang LL; Du Y; Chen R; Mao YH; Yang SG; Huang J; Wang JT; Wang L; Tang L; Zhang JQ
Eur J Med Chem; 2020 Oct; 204():112637. PubMed ID: 32717477
[TBL] [Abstract][Full Text] [Related]
10. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.
Chen D; Lin X; Zhang C; Liu Z; Chen Z; Li Z; Wang J; Li B; Hu Y; Dong B; Shen L; Ji J; Gao J; Zhang X
Cell Death Dis; 2018 Jan; 9(2):123. PubMed ID: 29374144
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and structure-activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold.
Wurz RP; Liu L; Yang K; Nishimura N; Bo Y; Pettus LH; Caenepeel S; Freeman DJ; McCarter JD; Mullady EL; Miguel TS; Wang L; Zhang N; Andrews KL; Whittington DA; Jiang J; Subramanian R; Hughes PE; Norman MH
Bioorg Med Chem Lett; 2012 Sep; 22(17):5714-20. PubMed ID: 22832322
[TBL] [Abstract][Full Text] [Related]
12. The imidazo[1,2-a]pyridine ring system as a scaffold for potent dual phosphoinositide-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitors.
Stec MM; Andrews KL; Bo Y; Caenepeel S; Liao H; McCarter J; Mullady EL; San Miguel T; Subramanian R; Tamayo N; Whittington DA; Wang L; Wu T; Zalameda LP; Zhang N; Hughes PE; Norman MH
Bioorg Med Chem Lett; 2015 Oct; 25(19):4136-42. PubMed ID: 26298499
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of novel imidazo[4,5-b]pyridine based compounds as potent anticancer agents with CDK9 inhibitory activity.
Ghanem NM; Farouk F; George RF; Abbas SES; El-Badry OM
Bioorg Chem; 2018 Oct; 80():565-576. PubMed ID: 30025343
[TBL] [Abstract][Full Text] [Related]
14. The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.
Shukuya T; Yamada T; Koenig MJ; Xu J; Okimoto T; Li F; Amann JM; Carbone DP
J Thorac Oncol; 2019 Jun; 14(6):1061-1076. PubMed ID: 30825612
[TBL] [Abstract][Full Text] [Related]
15. Discovery of 4-phenyl-2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as potent and orally active PI3K/mTOR dual inhibitors.
Yan G; Pu C; Lan S; Zhong X; Zhou M; Hou X; Yang J; Shan H; Zhao L; Li R
Eur J Med Chem; 2019 Sep; 178():667-686. PubMed ID: 31228810
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a series of N-(5-(quinolin-6-yl)pyridin-3-yl)benzenesulfonamides as PI3K/mTOR dual inhibitors.
Zhang J; Lv X; Ma X; Hu Y
Eur J Med Chem; 2017 Feb; 127():509-520. PubMed ID: 28109945
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and structure-activity relationships of PI3K/mTOR dual inhibitors from a series of 2-amino-4-methylpyrido[2,3-d]pyrimidine derivatives.
Han F; Lin S; Liu P; Tao J; Yi C; Xu H
Bioorg Med Chem Lett; 2014 Sep; 24(18):4538-4541. PubMed ID: 25139570
[TBL] [Abstract][Full Text] [Related]
18. Function-oriented synthesis of Imidazo[1,2-a]pyrazine and Imidazo[1,2-b]pyridazine derivatives as potent PI3K/mTOR dual inhibitors.
Li C; Han Y; Wang Z; Yu Y; Wang C; Ren Z; Guo Y; Zhu T; Li X; Dong S; Ma M
Eur J Med Chem; 2023 Feb; 247():115030. PubMed ID: 36586298
[TBL] [Abstract][Full Text] [Related]
19. Discovery of benzenesulfonamide derivatives as potent PI3K/mTOR dual inhibitors with in vivo efficacies against hepatocellular carcinoma.
Chen Y; Zhang L; Yang C; Han J; Wang C; Zheng C; Zhou Y; Lv J; Song Y; Zhu J
Bioorg Med Chem; 2016 Mar; 24(5):957-66. PubMed ID: 26819001
[TBL] [Abstract][Full Text] [Related]
20. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM
J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
